What went wrong with Novo Nordisk’s CagriSema obesity drug trial
5 days ago · The phase three trial for CagriSema involved around 3,400 participants with obesity or those who were overweight with one or more comorbidities and lasted for 68 weeks. The study followed a flexible protocol, enabling patients to adjust their dosage throughout. By the trial’s conclusion, just 57.3% of those on CagriSema reached the highest dose.
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · The data from Novo's CagriSema Phase III trial was based on about 3,400 people with a body mass index (BMI) of 30 or above or people with a BMI of 27 and at least one weight-related comorbidity ...
Novo Nordisk A/S: CagriSema demonstrates superior weight
Dec 20, 2024 · In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in …
5 days ago · CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. ... Following the news, shares of Novo Nordisk’s archrival in the obesity market space ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · The 68-week study showed participants on CagriSema lost about 23% of their body weight, compared with 12% for those taking cagrilintide by itself, 16% for those on semaglutide, and 2.3% for people ...
Novo’s next-gen obesity drug misses expectations in closely …
Dec 20, 2024 · The trial results announced Friday are a blow to Novo’s o besity ambitions, then, disappointing analysts and investors eager for signs it can continue to dominate a drug class projected to eventually surpass $100 billion in yearly sales. David Risinger, an analyst with Leerink Partners, wrote that, in light of the findings, “it …
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
Dec 20, 2024 · In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · The Danish company is now in late-stage testing with a dual-acting experimental drug it calls cagrisema. The drug combines semaglutide, the active ingredient in Wegovy, with another compound that mimics a metabolic hormone called amylin.
'A worst case scenario for Novo': Read the market reaction to CagriSema …
Dec 20, 2024 · Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected ...
Novo Nordisk affirms 25% weight-loss expectation for …
Nov 6, 2024 · Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new...